Stay updated on LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.

Latest updates to the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site footer’s revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check26 days agoChange DetectedA site-wide NIH banner says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference0.4%

- Check33 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check40 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1. The study record history remains unchanged.SummaryDifference0.1%

- Check61 days agoChange DetectedThe record history shows a new revision version, v3.7.0, has been added to replace the previous v3.6.6, signaling a page update to the study record.SummaryDifference0.1%

- Check82 days agoChange DetectedA new revision entry v3.6.6 has been added to the record history, replacing the previous v3.6.5 entry. This reflects the latest update to the ClinicalTrials.gov record for NCT01909453.SummaryDifference0.1%

Stay in the know with updates to LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.